Literature DB >> 3311315

Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors; sex steroid metabolism, immunologic response, and chronobiologic factors in tumor growth and therapy.

W Regelson1, W Pierpaoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3311315

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  12 in total

Review 1.  The therapeutic potential of melatonin: a review of the science.

Authors:  Samir Malhotra; Girish Sawhney; Promila Pandhi
Journal:  MedGenMed       Date:  2004-04-13

2.  Seasonal pattern of melatonin excretion in humans: relationship to daylength variation rate and geomagnetic field fluctuations.

Authors:  T J Paparrigopoulos; C N Stefanis
Journal:  Experientia       Date:  1996-03-15

3.  Pineal control of aging: effect of melatonin and pineal grafting on aging mice.

Authors:  W Pierpaoli; W Regelson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

4.  Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.

Authors:  P Lissoni; G Tancini; S Barni; F Paolorossi; A Ardizzoia; A Conti; G Maestroni
Journal:  Support Care Cancer       Date:  1997-03       Impact factor: 3.603

5.  Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.

Authors:  P Lissoni; S Pittalis; A Ardizzoia; F Brivio; S Barni; G Tancini; F Pelizzoni; G J Maestroni; B Zubelewicz; R Braczkowski
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

6.  A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.

Authors:  P Lissoni; S Barni; V Fossati; A Ardizzoia; M Cazzaniga; G Tancini; F Frigerio
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

7.  Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients.

Authors:  Giuseppina Messina; Paolo Lissoni; Paolo Marchiori; Erio Bartolacelli; Fernando Brivio; Luciano Magotti
Journal:  J Res Med Sci       Date:  2010-07       Impact factor: 1.852

8.  A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.

Authors:  P Lissoni; F Paolorossi; G Tancini; A Ardizzoia; S Barni; F Brivio; G J Maestroni; M Chilelli
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

9.  Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.

Authors:  V Martín; A M Sanchez-Sanchez; F Herrera; C Gomez-Manzano; J Fueyo; M A Alvarez-Vega; I Antolín; C Rodriguez
Journal:  Br J Cancer       Date:  2013-04-30       Impact factor: 7.640

10.  Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.

Authors:  P Lissoni; S Barni; S Meregalli; V Fossati; M Cazzaniga; D Esposti; G Tancini
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.